Clinical Trials | April 22, 2026
Novo Nordisk’s Etavopivat delivers major Phase 3 win in sickle cell disease
By cutting pain crises & boosting haemoglobin
By cutting pain crises & boosting haemoglobin
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
The programme integrates simulation-based training, expert-led sessions, and case-based discussions
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
The unit is equipped with advanced monitoring systems and supported by a multidisciplinary team
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
The new facility is expected to significantly improve access to high-quality medical services for patients across Gujarat and neighbouring regions
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
The programme has already drawn over 120 complex percutaneous coronary intervention (PCI) case submissions from across the country
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
